237 related articles for article (PubMed ID: 16928604)
1. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
2. Improved blood compatibility of a stent graft by combining heparin coating and abciximab.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Thromb Res; 2005; 115(3):245-53. PubMed ID: 15617748
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
4. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
[TBL] [Abstract][Full Text] [Related]
5. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S; Tamura N; Ishida H; Ruggeri ZM
J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
[TBL] [Abstract][Full Text] [Related]
6. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Storey RF; Oldroyd KG; Wilcox RG
Thromb Haemost; 2001 Mar; 85(3):401-7. PubMed ID: 11307804
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Storey RF; Judge HM; Wilcox RG; Heptinstall S
Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Behan MW; Fox SC; Heptinstall S; Storey RF
Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
[TBL] [Abstract][Full Text] [Related]
9. Coagulation and complement activation.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Biomaterials; 2001 Feb; 22(4):349-55. PubMed ID: 11205438
[TBL] [Abstract][Full Text] [Related]
10. Platelet activation after stenting with heparin-coated versus noncoated stents.
Gurbel PA; Bliden KP
Am Heart J; 2003 Oct; 146(4):E10. PubMed ID: 14564333
[TBL] [Abstract][Full Text] [Related]
11. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation.
Monnink SH; van Boven AJ; Peels HO; Tigchelaar I; de Kam PJ; Crijns HJ; van Oeveren W
J Investig Med; 1999 Jul; 47(6):304-10. PubMed ID: 10431485
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
13. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Leon C; Ravanat C; Freund M; Cazenave JP; Gachet C
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1941-7. PubMed ID: 12933533
[TBL] [Abstract][Full Text] [Related]
14. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
15. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ
Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836
[TBL] [Abstract][Full Text] [Related]
16. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Storey RF; May JA; Heptinstall S
Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
[TBL] [Abstract][Full Text] [Related]
18. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
Hardy AR; Hill DJ; Poole AW
Platelets; 2005 Nov; 16(7):415-29. PubMed ID: 16236603
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
[TBL] [Abstract][Full Text] [Related]
20. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.
Nylander S; Mattsson C; Ramström S; Lindahl TL
Br J Pharmacol; 2004 Aug; 142(8):1325-31. PubMed ID: 15265806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
